Placebo + JNJ-42160443
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystitis, Interstitial
Conditions
Cystitis, Interstitial, Urologic Diseases, Urinary Bladder Diseases, Cystitis
Trial Timeline
Apr 6, 2010 → Jun 24, 2011
NCT ID
NCT01060254About Placebo + JNJ-42160443
Placebo + JNJ-42160443 is a phase 2 stage product being developed by Johnson & Johnson for Cystitis, Interstitial. The current trial status is terminated. This product is registered under clinical trial identifier NCT01060254. Target conditions include Cystitis, Interstitial, Urologic Diseases, Urinary Bladder Diseases.
What happened to similar drugs?
2 of 5 similar drugs in Cystitis, Interstitial were approved
Approved (2) Terminated (2) Active (2)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01060254 | Phase 2 | Terminated |
Competing Products
19 competing products in Cystitis, Interstitial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ferumoxytol + Gadobutrol | Lipella Pharmaceuticals | Phase 1 | 19 |
| LP-10 | Lipella Pharmaceuticals | Phase 2 | 25 |
| LP-08 80mg + Normal saline + LP-08 20mg | Lipella Pharmaceuticals | Phase 2 | 25 |
| ASP3652 + Placebo | Astellas Pharma | Phase 2 | 35 |
| Mirabegron + Placebo | Astellas Pharma | Phase 3 | 32 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 42 |
| Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg | Johnson & Johnson | Approved | 35 |
| BOTOX + Placebo for BOTOX | AbbVie | Phase 2 | 35 |
| Rocuronium | Merck | Approved | 43 |
| Cidofovir | Gilead Sciences | Pre-clinical | 18 |
| PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685 | Pfizer | Phase 2 | 35 |
| Tanezumab + Tanezumab + Tanezumab + Tanezumab | Pfizer | Phase 2 | 27 |
| ERB-041 | Pfizer | Pre-clinical | 18 |
| PF-04383119 + Placebo | Pfizer | Phase 2 | 35 |
| Certolizumab pegol + Placebo | UCB | Phase 3 | 40 |
| moxifloxacin | Bayer | Phase 3 | 37 |
| Cipro (Ciprofloxacin, BAYQ3939) | Bayer | Pre-clinical | 23 |
| IW-3300 rectal foam + Placebo | Ironwood Pharmaceuticals | Phase 2 | 21 |
| MN-001 BID + MN-001 + Placebo | MediciNova | Phase 2 | 25 |